Combination of 9MW2821 and Toripalimab for advanced bladder cancer

A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study of 9MW2821 in Combination With Toripalimab Versus Standard Chemotherapy in First-line Locally Advanced or Metastatic Urothelial Cancer

This study is testing if a new combination of two drugs, 9MW2821 and Toripalimab, can help people with advanced bladder cancer do better than the usual chemotherapy.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 460 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. (Industry-sponsored)
• Drugs / interventions: chemotherapy, Toripalimab
• Locations: 1 site (Shanghai, Shanghai Municipality)
• Trial ID: NCT06592326 on ClinicalTrials.gov

What this trial studies

This phase 3 clinical study aims to evaluate the efficacy, safety, and immunogenicity of the combination of 9MW2821 and Toripalimab compared to standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma. Approximately 460 participants who have not received prior systemic treatment will be enrolled. The study will assess the outcomes based on measurable lesions and adequate organ function, ensuring participants meet specific eligibility criteria.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 80 with unresectable locally advanced or metastatic urothelial cancer who have not received prior treatment.

Not a fit: Patients with a history of another malignancy, autoimmune diseases requiring systemic treatment, or significant cardiovascular issues may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients with advanced bladder cancer.

How similar studies have performed: Other studies have shown promise in combining immunotherapy with chemotherapy for similar conditions, suggesting potential success for this approach.

Eligibility criteria

Inclusion Criteria:

* Sign the informed consent form approved by IEC.
* Male or female subjects aged 18 to 80 years.
* ECOG status: 0 or 1.
* Histologically confirmed local advanced or metastatic urothelial cancer
* Previously untreated with local advanced or metastatic urothelial cancer
* At least one measurable lesion, according to RECIST V1.1.
* Adequate tumor tissues submitted for test
* Suitable for cisplatin/carboplatin-based chemotherapy assessed by investigator
* Life expectancy for more than 12 weeks.
* Adequate organ functions.
* Proper contraception methods.
* Willingness to follow the study procedures.

Exclusion Criteria:

* History of another malignancy within 3 years.
* History of autoimmune disease requiring systemic treatment within 2 years.
* History of clinically significant cardiac/cerebrovascular diseases or thrombosis within 6 months.
* Major surgery treated within 28 days; Any live vaccines got within 28 days; Radiotherapy or Intravesical therapy treated within 21 days; Traditional Chinese medicine or any potent CYP3A4 inducers/inhibitors taken within 14 days.
* Lots of pleural fluid and ascites, uncontrolled bone pain or spinal compression existed within 14 days; Systemic treatment with active infection within 7 days.
* Previously treated with PD-1, PD-L1, PD-L2, CTLA-4 inhibitors; Previously treated with ADCs which target Nectin-4 or are conjugated with payload MMAE; Organ transplantation or allogeneic hematopoietic stem cell transplantation in the past.
* Clinical significantly toxicity Grade ≥ 2 (except alopecia and pigmentation) related to previous treatment.
* Any situations adding the risk of severe dry eye, active keratitis or corneal ulcer, etc.
* Peripheral neuropathy Grade ≥ 2.
* Any other serious chronic or uncontrolled disease.
* Uncontrolled central nervous system metastases or carcinomatous meningitis.
* Active HBV/HCV/HIV infection, etc.
* Known allergic sensitivity to any of the ingredients of the study drug.
* History of drug abuse or mental illness.
* Other conditions unsuitable into the study.

Where this trial is running

Shanghai, Shanghai Municipality

• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (Recruiting)

Study contacts

• Study coordinator: Dingwei Ye, Professor

Conditions Urothelial Carcinoma